Indolent Lymphoma is a slow-growing form of Non-Hodgkin Lymphoma (NHL) that originates from lymphocytes. According to Junjie Huang et al., 2024, NHL is a blood-related malignancy and accounts for 90% of all malignant lymphomas. Indolent lymphoma represents a significant portion of NHL cases and often requires long-term management. According to the indolent lymphoma pipeline analysis by Expert Market Research, the treatment landscape is witnessing growth due to the rising focus on targeted therapies and immunotherapies. The development of novel indolent lymphoma drugs and improved diagnostic techniques is expected to drive market expansion in the coming years.
Major companies involved in the indolent lymphoma pipeline analysis include Shanghai YingLi Pharmaceutical Co. Ltd., Kyowa Kirin Co., Ltd., and others.
Leading drugs currently in the pipeline include ME-401¸ BI-1206, EO2463, and others.
The pipeline growth for indolent lymphoma drugs is expected due to rising prevalence, increased investment in targeted biologics, and ongoing clinical trials focused on novel monoclonal antibodies and combination therapies.
The Indolent Lymphoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into indolent lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for indolent lymphoma. The indolent lymphoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The indolent lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with indolent lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to indolent lymphoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Indolent lymphoma is a type of non-Hodgkin lymphoma that is mostly slow-growing and typically originates in B-cells. It occurs when genetic mutations cause abnormal lymphocytes to accumulate in lymph nodes or bone marrow, disrupting normal immune function. It often presents with painless swelling in lymph nodes and progresses gradually, sometimes without symptoms for years.
Indolent lymphoma is treated with targeted therapies, immunotherapy, chemotherapy, or radiation, depending on disease stage and symptoms. Some cases may be managed with active surveillance. In February 2025, the U.S. Food and Drug Administration approved brentuximab vedotin combined with lenalidomide and rituximab for relapsed large B-cell lymphoma arising from indolent lymphoma, offering improved overall survival and response rates in ineligible transplant patients.
Indolent lymphoma, a subtype of non-hodgkin lymphoma (NHL), is an active area of research amongst other oncology drug pipelines. According to Junjie Huang et al., 2024, NHL accounts for 90% of all malignant lymphomas, with key types being diffuse large B-cell lymphoma and follicular lymphoma. NHL represented 2.8% of global cancer cases and 2.6% of cancer-related deaths in 2020. As per the National Cancer Institute, the United States is projected to report 80,350 new NHL cases and 19,390 deaths in 2025, highlighting the demand for innovative treatments.
This section of the report covers the analysis of indolent lymphoma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II accounts for 51%, covering a major share of the total indolent lymphoma clinical trials. Phase I follows with 40%, highlighting robust early-stage innovation. Phase III holds around 7%, indicating promising near-commercial therapies. This balanced pipeline supports future growth and therapeutic advancements in the indolent lymphoma market.
The drug molecule categories covered under the indolent lymphoma pipeline analysis include small molecules, monoclonal antibodies, biologics, cell therapies, and immunomodulators. The indolent lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for indolent lymphoma. Monoclonal antibody-based therapies continue to dominate the indolent lymphoma pipeline with promising developments. For instance, Monjuvi (tafasitamab), an anti-CD19 monoclonal antibody, in combination with Rituxan and Revlimid, demonstrated positive results in the Phase III Inmind trial for relapsed or refractory follicular lymphoma. A regulatory filing for this indication is planned in the United States by the end of 2024.
The EMR report for the indolent lymphoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed indolent lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in indolent lymphoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for indolent lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of indolent lymphoma drug candidates.
Zandelisib (ME-401), sponsored by Kyowa Kirin Co., Ltd., is currently under evaluation in a Phase 2 study for Japanese patients with relapsed or refractory indolent B-cell Non-Hodgkin's lymphoma. This study is assessing the drug’s efficacy, safety, and pharmacokinetics. Zandelisib is a potent and selective PI3Kδ inhibitor, functioning as an antineoplastic agent targeting cancer cell survival pathways.
BI-1206 is a high-affinity monoclonal antibody targeting FcγRIIB (CD32B), currently being evaluated in a Phase 1/2a trial sponsored by BioInvent International AB. The study is assessing its combination with rituximab, with or without acalabrutinib, in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma. This phase aims to determine safety, optimal dosing, and preliminary efficacy while enhancing anti-CD20 therapy response. BI-1206 blocks FcγRIIB (CD32B), an inhibitory receptor that limits antibody therapies, thereby restoring and enhancing rituximab’s anti-tumor activity.
EO2463, sponsored by Enterome, is currently undergoing a global Phase 1/2 trial to evaluate its recommended Phase 2 dose, safety, tolerability, immunogenicity, and preliminary efficacy in patients with indolent non-Hodgkin lymphoma. This novel, off-the-shelf peptide therapeutic vaccine is targeting malignant B lymphocytes by mimicking CD20, CD22, CD37, and BAFF-R markers. It is being administered as monotherapy and in combination with lenalidomide and/or rituximab.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Indolent Lymphoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for indolent lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into indolent lymphoma collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share